ReviewInternational journal of cell biology2013
Small-molecule theranostic probes: a promising future in neurodegenerative diseases.
Review in International journal of cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer's Disease-Are There Connections?International journal of molecular sciences · 2025Review
- Bovine spongiform encephalopathy: A review of current knowledge and challenges.Open veterinary journal · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Targeted Nanotheransotics: Integration of Preclinical MRI and CT in the Molecular Imaging and Therapy of Advanced Diseases.Nanotheranostics · 2024Review
- Natural Product-based Nanomedicine: Recent Advances and Issues for the Treatment of Alzheimer's Disease.Current neuropharmacology · 2022Article
- Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs.Pharmaceutics · 2021Review
- Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.Biomaterials science · 2020Article
- Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020).International journal of nanomedicine · 2020Review
- Prion-Like Mechanisms in Parkinson's Disease.Frontiers in neuroscience · 2019Review
- Peroxynitrite Activated Drug Conjugate Systems Based on a Coumarin Scaffold Toward the Application of Theranostics.Frontiers in chemistry · 2019Article
- Serum and Urine Thioflavin-T-Enhanced Fluorescence in Severe Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2018Article
- Bioprocess and downstream optimization of recombinant human growth hormone inResearch in pharmaceutical sciences · 2018Article
- Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer.International journal of nanomedicine · 2018Article
- Oligomerization Alters Binding Affinity Between Amyloid Beta and a Modulator of Peptide Aggregation.The journal of physical chemistry. C, Nanomaterials and interfaces · 2017Article
- Dual-Responsive Molecular Probe for Tumor Targeted Imaging and Photodynamic Therapy.Theranostics · 2017Article
- Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.Current Alzheimer research · 2017Review
- A Metal-Free Method for Producing MRI Contrast at Amyloid-β.Journal of Alzheimer's disease : JAD · 2017Article
- Protective V127 prion variant prevents prion disease by interrupting the formation of dimer and fibril from molecular dynamics simulations.Scientific reports · 2016Article
- Congo red modulates ACh-induced Ca(2+) oscillations in single pancreatic acinar cells of mice.Acta pharmacologica Sinica · 2014Article
- A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease.Chemical communications (Cambridge, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prion diseases are fatal neurodegenerative illnesses, which include Creutzfeldt-Jakob disease in humans and scrapie, chronic wasting disease, and bovine spongiform encephalopathy in animals. They are caused by unconventional infectious agents consisting primarily of misfolded, aggregated, β -sheet-rich isoforms, denoted prions, of the physiological cellular prion protein (PrP(C)). Many lines of evidence suggest that prions (PrP(Sc)) act both as a template for this conversion and as a neurotoxic agent causing neuronal dysfunction and cell death. As such, PrP(Sc) may be considered as both a neuropathological hallmark of the disease and a therapeutic target. Several diagnostic imaging probes have been developed to monitor cerebral amyloid lesions in patients with neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, and prion disease). Examples of these probes are Congo red, thioflavin T, and their derivatives. We synthesized a series of styryl derivatives, denoted theranostics, and studied their therapeutic and/or diagnostic potentials. Here we review the salient traits of these small molecules that are able to detect and modulate aggregated forms of several proteins involved in protein misfolding diseases. We then highlight the importance of further studies for their practical implications in therapy and diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.